Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 4:11:1399665.
doi: 10.3389/fmed.2024.1399665. eCollection 2024.

Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients

Wenjuan Zhao  1 , Yi Liu  1 , Mengdi Zhang  2 , Zixin Cui  1 , Zhan Qu  1 , Yiyang Li  1 , Meijuan Wan  1 , Wen Wang  1 , Yunru Chen  1 , Lei Shi  1 , Jianzhou Li  1 , Feng Ye  1
Affiliations

Lipid safety of tenofovir alafenamide during 96-week treatment in treatment-naive chronic hepatitis B patients

Wenjuan Zhao et al. Front Med (Lausanne). .

Abstract

Background: This study was aimed at investigating the dynamics of lipids and the effect of TAF on the lipid profile of patients including fatty liver disease in CHB patients.

Methods: The data of TC, LDL-c, HDL-c, TG, and TC/HDL ratio were collected at baseline, 24 weeks, 48 weeks, 72 weeks, and 96 weeks. CHB patients with fatty liver at baseline were further analyzed in a subgroup.

Results: A total of 137 CHB patients treated with TAF were enrolled in this study. During 96 weeks of TAF treatment, there was no significant change in TC, LDL-c, HDL-c, and TG level (P > 0.05). The TC/HDL-c ratio was increased with no significant change (+0.24, P > 0.05). In CHB patients with fatty liver (n = 48), TC, LDL-c, and TC/HDL-c ratio increased gradually during TAF treatment, TG levels increased to 146.63 mg/dL at 48 weeks (P = 0.057) and then decreased, but there was still no significant change compared with the baseline level by 96 weeks (P > 0.05).

Conclusion: TAF treatment had a low effect on the lipid profile of CHB patients over the course of 96 weeks, and it was safe even in patients with fatty liver.

Clinical trial registration: [https://www.chictr.org.cn/showproj.html?proj=65123], identifier [ChiCTR2000041005].

Keywords: 96-week; chronic hepatitis B; lipid safety; tenofovir alafenamide; treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Study flowchart. TDF, tenofovir disoproxil fumarate; ETV, entecavir; IFN, interferon; HCC, hepatocellular carcinoma.
FIGURE 2
FIGURE 2
Virological response outcome before and after 24, 48, 72 and 96 weeks of TAF treatment in HBV patients. HBV-DNA, hepatitis B virus-deoxyribonucleic acid; ALT, alanine transaminase.
FIGURE 3
FIGURE 3
Changes in serum lipoproteins before and after 24, 48, 72, and 96 weeks of univariate analysis of TAF treatment in HBV patients. (A) Changes in Lipid Levels in Overall Patients After Treatment with TAF (0W: n = 137, 24W: n = 137, 48W: n = 89, 72W: n = 62, 96W: n = 60). (B) Changes in blood lipid profile in a small sample of HBV patients with a complete follow-up of 96 weeks after treatment with TAF (n = 36). TC, Total Cholesterol; LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein; TG, Triglyceride. The data were shown as the median (IQR).
FIGURE 4
FIGURE 4
Changes in relative baseline lipid levels after TAF treatment in HBV patients with NHC (n = 56) and HC (n = 81). NHC, non-hypercholesterolemia; HC, hypercholesterolemia; TC, Total Cholesterol; LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein; TG, Triglyceride. The data were shown as the median (IQR).
FIGURE 5
FIGURE 5
Changes in the lipid levels during TAF treatment in HBV patients with fatty liver (n = 48) and non-fatty liver (n = 89). TC, Total Cholesterol; LDL, Low Density Lipoprotein; HDL, High Density Lipoprotein; TG, Triglyceride. The data were shown as median (IQR).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Yuen M, Chen D, Dusheiko G, Janssen H, Lau D, Locarnini S. Hepatitis B virus infection. Nat Rev Dis Primers. (2018) 4:18036. 10.1038/nrdp.2018.35 - DOI - PubMed
    1. Jeng W-J, Papatheodoridis GV, Lok ASF. Hepatitis B. Lancet. (2023) 401:1039–52. 10.1016/S0140-6736(22)01468-4 - DOI - PubMed
    1. Terrault NA, Lok ASF, Mcmahon BJ, Chang K-M, Hwang JP, Jonas MM. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. (2018) 67:1560–99. 10.1002/hep.29800 - DOI - PMC - PubMed
    1. Babusis D, Phan TK, Lee WA, Watkins WJ, Ray AS. Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340. Mol Pharmaceutics. (2013) 10:459–66. 10.1021/mp3002045 - DOI - PubMed
    1. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. (2017) 67:370–98. - PubMed